Evidence map›Paper›PMID 29053874›Full record

ArticleBrain : a journal of neurology2017

Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.

Alexandre Bejanin, Daniel R Schonhaut, Renaud La Joie, Joel H Kramer, Suzanne L Baker, Natasha Sosa, Nagehan Ayakta, Averill Cantwell, Mustafa Janabi, Mariella Lauriola and 7 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05020626 (Modelling Tau Deposition and Distribution From Diffusion Tensor Imaging With Generative Adversarial Network for Alzheimer's Disease Diagnosis), which is not on this map. Cited by 455 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
455citing papers in PubMed, 5 pooled it
31.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05020626 recruitingnot on this mapstarted 2021, after this paper: background citation

Modelling Tau Deposition and Distribution From Diffusion Tensor Imaging With Generative Adversarial Network for Alzheimer's Disease Diagnosis

TypeobservationalSponsorChinese University of Hong KongRan2021 to 2025Enrolled250ConditionsAlzheimer's Disease Diagnosis
3 · Its place in the literature

Who cites it

455 citing papers in PubMed, 5 syntheses or guidelines pooled it, 768 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. [European journal of nuclear medicine and molecular imaging · 2026
    Article
  9. Brain microstructure mediates the relationship between Alzheimer's proteinopathies and memory.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  10. Article
  11. Article
  12. Sex specificity of resistance to caTAUstrophe.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

395 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Alexandre BejaninMemory and Aging Center, University of California San Francisco, San Francisco, CA, USA.
Daniel R SchonhautMemory and Aging Center, University of California San Francisco, San Francisco, CA, USA.
Renaud La JoieMemory and Aging Center, University of California San Francisco, San Francisco, CA, USA.
Joel H KramerMemory and Aging Center, University of California San Francisco, San Francisco, CA, USA.
Suzanne L BakerMolecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
Natasha SosaMemory and Aging Center, University of California San Francisco, San Francisco, CA, USA.
Nagehan AyaktaMemory and Aging Center, University of California San Francisco, San Francisco, CA, USA.
Averill CantwellMemory and Aging Center, University of California San Francisco, San Francisco, CA, USA.
Mustafa JanabiMolecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
Mariella LauriolaMemory and Aging Center, University of California San Francisco, San Francisco, CA, USA.
James P O'NeilMolecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
Maria L Gorno-TempiniMemory and Aging Center, University of California San Francisco, San Francisco, CA, USA.
Zachary A MillerMemory and Aging Center, University of California San Francisco, San Francisco, CA, USA.
Howard J RosenMemory and Aging Center, University of California San Francisco, San Francisco, CA, USA.
Bruce L MillerMemory and Aging Center, University of California San Francisco, San Francisco, CA, USA.
William J JagustMolecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
Gil D RabinoviciMemory and Aging Center, University of California San Francisco, San Francisco, CA, USA.
University Memory and Aging Center · USLawrence Berkeley National Laboratory · USUniversity of California, San Francisco · US

Funding

TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, BRUCE L · 2004 to 2018
$27.1M
The Four Repeat Tauopathy Neuroimaging InitiativeR01AG038791 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2010 to 2020
$18.1M
Neural and Biochemical Mechanisms of Cognitive AgingR01AG034570 · NIA · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI William J. Jagust · 2009 to 2026
$12.0M
Progressive Aphasia Cognition Anatomy and ProgressionR01NS050915 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARIA LUISA GORNO TEMPINI · 2004 to 2026
$11.0M
Training - The Frontotemporal Lobar Degeneration Clinical Research ConsortiumU54NS092089 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2014 to 2018
$6.4M
Connectomic imaging in familial and sporadic frontotemporal degenerationU01AG052943 · NIA · UNIVERSITY OF PENNSYLVANIA · PI GORNO TEMPINI, MARIA LUISA, GROSSMAN, MURRAY · 2016 to 2019
$5.9M
Early Age-of-Onset AD: Clinical Heterogeneity and Network DegenerationR01AG045611 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RABINOVICI, GIL DAN · 2014 to 2018
$3.1M
Training program in the neurology of language and neurodegenerative aphasiasK24DC015544 · NIDCD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GORNO TEMPINI, MARIA LUISA · 2016 to 2025
$1.9M
Multimodal Imaging in Frontotemporal DegenerationK24AG045333 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSEN, HOWARD J · 2013 to 2023
$1.9M
Neurodevelopmental Trajectories Towards Neurodegenerative DiseaseK23AG048291 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, ZACHARY A · 2015 to 2019
$912k
NIA NIH HHS K23 AG048291NIA NIH HHS K24 AG045333NIA NIH HHS P01 AG019724NIA NIH HHS P50 AG023501NIA NIH HHS R01 AG034570NIA NIH HHS R01 AG038791NIA NIH HHS R01 AG045611NIA NIH HHS U01 AG052943NIDCD NIH HHS K24 DC015544NINDS NIH HHS R01 NS050915NINDS NIH HHS U54 NS092089
6 · The paper itself

Abstract

Neuropathological and in vivo studies have revealed a tight relationship between tau pathology and cognitive impairment across the Alzheimer's disease spectrum. However, tau pathology is also intimately associated with neurodegeneration and amyloid pathology. The aim of the present study was therefore to assess whether grey matter atrophy and amyloid pathology contribute to the relationship between tau pathology, as measured with 18F-AV-1451-PET imaging, and cognitive deficits in Alzheimer's disease. We included 40 amyloid-positive patients meeting criteria for mild cognitive impairment due to Alzheimer's disease (n = 5) or probable Alzheimer's disease dementia (n = 35). Twelve patients additionally fulfilled the diagnostic criteria for posterior cortical atrophy and eight for logopenic variant primary progressive aphasia. All participants underwent 3 T magnetic resonance imaging, amyloid (11C-PiB) positron emission tomography and tau (18F-AV-1451) positron emission tomography, and episodic and semantic memory, language, executive and visuospatial functions assessment. Raw cognitive scores were converted to age-adjusted Z-scores (W-scores) and averaged to compute composite scores for each cognitive domain. Independent regressions were performed between 18F-AV-1451 binding and each cognitive domain, and we used the Biological Parametric Mapping toolbox to further control for local grey matter volumes, 11C-PiB uptake, or both. Partial correlations and causal mediation analyses (mediation R package) were then performed in brain regions showing an association between cognition and both 18F-AV-1451 uptake and grey matter volume. Our results showed that decreased cognitive performance in each domain was related to increased 18F-AV-1451 binding in specific brain regions conforming to established brain-behaviour relationships (i.e. episodic memory: medial temporal lobe and angular gyrus; semantic memory: left anterior temporal regions; language: left posterior superior temporal lobe and supramarginal gyrus; executive functions: bilateral frontoparietal regions; visuospatial functions: right more than left occipitotemporal regions). This pattern of regional associations remained essentially unchanged-although less spatially extended-when grey matter volume or 11C-PiB uptake maps were added as covariates. Mediation analyses revealed both direct and grey matter-mediated effects of 18F-AV-1451 uptake on cognitive performance. Together, these results show that tau pathology is related in a region-specific manner to cognitive impairment in Alzheimer's disease. These regional relationships are weakly related to amyloid burden, but are in part mediated by grey matter volumes. This suggests that tau pathology may lead to cognitive deficits through a variety of mechanisms, including, but not restricted to, grey matter loss. These results might have implications for future therapeutic trials targeting tau pathology.

Indexed as

AgedAlzheimer DiseaseAmyloidAniline CompoundsAphasia, Primary ProgressiveBenzothiazolesBrainCarbolinesCarbon RadioisotopesCase-Control StudiesCognitive DysfunctionFemaleFluorine RadioisotopesHumansMagnetic Resonance ImagingMale2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleAmyloidAniline CompoundsBenzothiazolesCarbolinesCarbon RadioisotopesFluorine RadioisotopesMAPT protein, humantau ProteinsThiazolesAlzheimer’s diseaseamyloidatrophycognitive impairmenttau

Identifiers

PMID29053874
PMCPMC5841139
OpenAlexW2763470121

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.